Conduit and Agility to Develop Enhanced Formulations for its Autoimmune Pipeline
Conduit has developed a series of novel, advantageous solid forms of all its autoimmune pipeline assets, each protected by newly established composition-of-matter intellectual property (IP).
Autoimmune Pipeline | 23/01/2025 | By Aishwarya | 464
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy